Colorectal Cancer at Fudan University Shanghai Cancer Center | CMCS

Expert Colorectal Cancer Surgery & Treatment in Shanghai

The Department of Colorectal Surgery at Fudan University Shanghai Cancer Center (FUSCC) is one of China's most distinguished centers for the surgical and multidisciplinary management of colorectal cancer, with a national reputation for excellence in minimally invasive and robotic colorectal surgery, rectal cancer sphincter preservation, liver metastasis management, peritoneal metastasis treatment with CRS-HIPEC, and precision oncology for advanced colorectal cancer. With one of the highest volumes of colorectal cancer surgery in China, the department combines surgical excellence with a world-class research program and a fully integrated multidisciplinary approach.

For international patients with colorectal cancer — whether seeking surgical treatment, a second opinion, access to novel targeted therapies or immunotherapy, or expert management of metastatic or recurrent disease — FUSCC's colorectal surgery department offers an unparalleled combination of expertise, volume, and research leadership. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey at FUSCC.

About the Department

FUSCC's colorectal surgery department is a national key clinical specialty performing thousands of colorectal cancer operations annually. The department operates dedicated colorectal surgical wards, a comprehensive outpatient colorectal oncology clinic, a colorectal cancer MDT, a minimally invasive and robotic colorectal surgery program, a CRS-HIPEC program for peritoneal metastases, and works in close collaboration with medical oncology, radiation oncology, interventional radiology, pathology, and molecular diagnostics through a fully integrated multidisciplinary team.

Faculty members publish regularly in leading colorectal oncology journals including Journal of Clinical Oncology, Annals of Oncology, Annals of Surgery, Diseases of the Colon & Rectum, and Colorectal Disease.

Conditions Treated

Colon Cancer

• Stage I-III Colon Cancer — Laparoscopic and robotic colectomy with complete mesocolic excision (CME) and central vascular ligation (CVL); right, left, sigmoid, and total colectomy; adjuvant FOLFOX or CAPOX for stage III and high-risk stage II
• Stage IV Colon Cancer with Resectable Liver Metastases — Synchronous or staged resection of primary and liver metastases; perioperative FOLFOX/FOLFIRI + bevacizumab or cetuximab
• MSI-H/dMMR Colon Cancer — Pembrolizumab for stage IV MSI-H disease; consideration of immunotherapy for stage III MSI-H
• BRAF V600E-Mutated Colon Cancer — Encorafenib + cetuximab for metastatic disease
• RAS Wild-Type Colon Cancer — Cetuximab and panitumumab combinations for left-sided RAS/BRAF wild-type metastatic disease
• HER2-Amplified Colon Cancer — Trastuzumab + pertuzumab; trastuzumab deruxtecan
• Hereditary Colorectal Cancer — Lynch syndrome, FAP, and MUTYH-associated polyposis; genetic counseling and surveillance; prophylactic colectomy for FAP

Rectal Cancer

• Early Rectal Cancer (T1-T2) — Transanal endoscopic microsurgery (TEM) and transanal minimally invasive surgery (TAMIS) for selected T1 tumors; low anterior resection for T2 tumors
• Locally Advanced Rectal Cancer (T3-T4, N+) — Total neoadjuvant therapy (TNT): FOLFOX/CAPOX induction followed by long-course chemoradiation, or short-course radiation followed by FOLFOX; surgery after restaging
• Watch-and-Wait (W&W) — Non-operative management for patients achieving complete clinical response (cCR) after neoadjuvant therapy; one of China's most experienced W&W programs with rigorous surveillance protocols
• Low Anterior Resection (LAR) — Laparoscopic and robotic LAR with total mesorectal excision (TME); ultra-low anterior resection with coloanal anastomosis; defunctioning ileostomy
• Intersphincteric Resection (ISR) — Sphincter-preserving surgery for very low rectal cancer; partial, subtotal, and total ISR
• Abdominoperineal Resection (APR) — Extralevator APR (ELAPE) for low rectal cancer with levator involvement; perineal reconstruction
• Transanal Total Mesorectal Excision (TaTME) — Transanal approach for low rectal cancer in narrow pelvis or obese patients
• Locally Recurrent Rectal Cancer — Multivisceral resection for selected recurrences; pelvic exenteration; intraoperative radiation therapy (IORT)

Metastatic Colorectal Cancer

• Liver Metastases — Hepatic resection coordination with hepatobiliary surgery; two-stage hepatectomy and portal vein embolization; conversion chemotherapy for initially unresectable liver metastases; HAI (hepatic arterial infusion) pump coordination
• Lung Metastases — Pulmonary metastasectomy coordination with thoracic surgery; SBRT for oligometastatic lung disease
• Peritoneal Metastases — CRS-HIPEC for selected patients with limited peritoneal spread; PIPAC (pressurized intraperitoneal aerosol chemotherapy) for palliative management
• Oligometastatic Disease — Curative-intent local ablative therapy (RFA, MWA, SBRT) for limited metastatic disease

Anal Cancer

• Anal Squamous Cell Carcinoma — Concurrent chemoradiation (mitomycin C + 5-FU or capecitabine) as definitive treatment; pembrolizumab for recurrent/metastatic disease; APR for salvage surgery
• Anal Intraepithelial Neoplasia (AIN) — High-resolution anoscopy; topical therapy and ablation

Surgical Excellence

Robotic & Laparoscopic Colorectal Surgery

FUSCC's colorectal surgery department has been at the forefront of minimally invasive colorectal surgery in China:

• Robotic Total Mesorectal Excision (TME) — da Vinci robotic rectal cancer surgery with enhanced 3D visualization and instrument dexterity in the narrow pelvis; superior nerve preservation for urinary and sexual function
• Robotic Complete Mesocolic Excision (CME) — Robotic right colectomy with D3 lymphadenectomy
• Laparoscopic Colectomy & Anterior Resection — Standard minimally invasive approach for colon and rectal cancer
• Transanal Total Mesorectal Excision (TaTME) — Combined transabdominal and transanal approach for challenging low rectal cancers
• Single-Port Laparoscopic Surgery — For selected colonic procedures

Watch-and-Wait Program

FUSCC's watch-and-wait program is one of the most experienced in China, offering non-operative management for rectal cancer patients who achieve a complete clinical response (cCR) after total neoadjuvant therapy. The program follows rigorous surveillance protocols including:

• Regular digital rectal examination and endoscopy
• MRI assessment of tumor response
• CEA monitoring
• Salvage surgery for local regrowth

CRS-HIPEC Program

FUSCC's CRS-HIPEC program offers cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for selected patients with peritoneal metastases from colorectal cancer. This complex procedure — which removes all visible peritoneal disease followed by heated intraperitoneal oxaliplatin or mitomycin C — offers the possibility of long-term survival for carefully selected patients with limited peritoneal spread (PCI ≤20).

Colorectal Cancer MDT & Precision Oncology

All colorectal cancer cases at FUSCC are reviewed by the colorectal cancer MDT, integrating surgical, medical oncological, radiation oncological, interventional radiological, and pathological expertise. The MDT's precision oncology approach includes:

• RAS/BRAF/MSI/HER2 Testing — Mandatory molecular profiling for all metastatic colorectal cancer patients to guide targeted therapy selection
• Liquid Biopsy — ctDNA monitoring for treatment response and minimal residual disease after surgery
• NTRK Fusion Testing — Larotrectinib and entrectinib for NTRK-fused colorectal cancer
• HER2 Amplification Testing — Trastuzumab-based therapy for HER2-amplified metastatic CRC
• Tumor Sidedness — Right vs. left-sided primary tumor location guiding anti-EGFR therapy eligibility

Why International Patients Choose FUSCC Colorectal Surgery

• High-Volume Expertise — One of China's highest-volume colorectal cancer surgery programs
• Robotic Surgery Leadership — Robotic TME and CME for optimal oncological and functional outcomes
• Watch-and-Wait Expertise — One of China's most experienced W&W programs for complete responders after neoadjuvant therapy
• CRS-HIPEC Program — Expert peritoneal metastasis management for selected patients
• Precision Oncology — Comprehensive molecular profiling guiding targeted therapy and immunotherapy decisions
• Cost-Effectiveness — World-class colorectal cancer care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your diagnosis, imaging (CT, MRI, PET-CT), colonoscopy reports, biopsy pathology, molecular profiling (RAS, BRAF, MSI, HER2), and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate colorectal surgeon based on your tumor location and stage.
4. MDT Submission — Where appropriate, we facilitate pre-arrival case review by FUSCC's colorectal cancer MDT.
5. Priority Scheduling — We secure a consultation and surgical slot with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near FUSCC, and Shanghai airport transfers.
7. Surgical Admission Support — Full coordination of pre-operative assessment, neoadjuvant therapy scheduling if required, admission, and inpatient care.
8. Post-Operative Follow-Up — Pathology report translation, adjuvant therapy coordination, and remote follow-up after you return home.

Book a Consultation

If you are seeking expert colorectal cancer care in Shanghai — whether for colon cancer, rectal cancer, liver metastases, peritoneal metastases, or a second opinion on a colorectal diagnosis — CMCS can arrange a specialist consultation with FUSCC's colorectal surgery team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com